Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Launched by CHILDREN'S ONCOLOGY GROUP · Oct 28, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating whether adding a medication called levocarnitine to standard chemotherapy can help protect the liver in patients with certain types of leukemia or lymphoma. The trial focuses on young adults aged 15 to 39 who are newly diagnosed with B Acute Lymphoblastic Leukemia (ALL), T Acute Lymphoblastic Leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. Asparaginase, a common part of the chemotherapy treatment, can sometimes cause liver damage, especially in patients who may already have fat in their liver. By adding levocarnitine, which helps support liver health, the study aims to see if it can reduce the risk of liver problems during treatment.

To participate in this trial, patients need to meet specific criteria, such as being within the right age range and having a newly diagnosed type of leukemia or lymphoma. They'll undergo regular check-ups to monitor their liver function throughout the study. Importantly, this trial is currently recruiting participants, and anyone considering joining will need to provide written consent and meet health requirements. This study could potentially improve treatment outcomes for young patients facing these challenging conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \>= 15 and \< 40 years at time of diagnosis
• • Newly diagnosed B-ALL, T-ALL, lymphoblastic lymphoma (LLy), or mixed-phenotype acute leukemia/lymphoma (MPAL)
• • Note: Philadelphia chromosome (PH)+ and PH-like acute leukemia are eligible (use of tyrosine kinase inhibitors \[TKI\] or CRLF2- targeted concomitant medication must be documented, if used)
• • Conjugated bilirubin =\< 1.5 x upper limit of normal (ULN) for age, regardless of baseline bilirubin (within 7 days prior to enrollment), and
• • Serum glutamate pyruvate transaminase (SGPT) (ALT) =\< 225 U/L (=\< 5x ULN) (within 7 days prior to enrollment), and
• • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L and serum glutamic oxaloacetic transaminase (SGOT) (AST) to 50 U/L regardless of baseline
• • SGOT (AST) =\< 250 U/L (=\< 5x ULN) (within 7 days prior to enrollment)
• • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L and SGOT (AST) to 50 U/L regardless of baseline
• • For patients receiving ursodiol prior to enrollment, laboratory values must meet above criteria off ursodiol for 7 days
• * PEDIATRIC PATIENTS (AGE 15-17 years):
• • A 24-hour urine creatinine clearance \>= 30 mL/min/1.73 m\^2 (within 7 days prior to enrollment) OR
• * A glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m\^2. GFR must be performed using one of the following methods (within 7 days prior to enrollment):
• • 1. Estimated GFR (eGFR) \>= 30 mL/min/1.73 m\^2.
• • An online calculator is available through the National Kidney Foundation at https://www.kidney.org/professionals/kdoqi/gfr_calculatorped
• • 2. Measured GFR \>= 30 mL/min/1.73 m\^2 (any age). If measured GFR is used, it must be performed using direct measurement with a nuclear blood sampling method or small molecule clearance method (iothalamate or other molecule per institutional standard).
• • ADULT PATIENTS (AGE 18 YEARS OR OLDER): Creatinine clearance \>= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection (within 7 days prior to enrollment). Estimated creatinine clearance is based on actual body weight
• • An online calculator is available through the National Kidney Foundation at https://www.kidney.org/professionals/kdoqi/gfr_calculatorcoc
• • Berlin-Frankfurt-Munich (BFM), Children's Oncology Group (COG), or C10403-based Induction regimen and must be inclusive of \>= 1 dose of pegaspargase or calaspargase pegol, and
• • First dose of asparaginase must be planned within the first week of induction therapy, and
• • Dose of pegaspargase or calaspargase pegol must be \>= 1,000 IU/ m\^2 (dose-capping permitted per primary regimen)
• • Note: Co-enrollment on a therapeutic consortia trial is not required
• • All patients and/or their parents or legal guardians must sign a written informed consent
• • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
• Exclusion Criteria:
• • Down syndrome
• • Known inherited or autoimmune liver disease impacting conjugated bilirubin (e.g., Alagille syndrome, primary sclerosing cholangitis, other)
• • Known biopsy (or imaging) proven severe liver fibrosis (Batts-Ludwig \>= stage 3)
• • Unable to tolerate oral formulation of study drug at enrollment
• • Patients who received chemotherapy or treatment for a prior malignancy are not eligible
• • The following are permitted: steroid prophase, hydroxyurea, or other cytoreduction prior to initiation of Induction chemotherapy (must be documented) and chemotherapy for current diagnosis (i.e. initiation of Induction therapy within enrollment window). Chemotherapy prior to enrollment for treatment of a non-malignancy (e.g., steroid or methotrexate for autoimmune disease) is also permitted and must be documented
• • Female patients who are pregnant since fetal toxicities and teratogenic effects in humans are unknown for study drug. A pregnancy test is required for female patients of childbearing potential
• • Lactating females who plan to breastfeed their infants
• • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation